Eastman Kodak expands domestic pharma manufacturing to reduce shipping delays and import tariffs

Eastman Kodak expands domestic pharma manufacturing to reduce shipping delays and import tariffs
Kodak opens U.S. pharma facility

Eastman Kodak announced the launch of its new regulated pharmaceutical products, produced domestically at its cGMP facility in Rochester, New York.

By manufacturing these products in the U.S., the company aims to eliminate import tariffs and avoid overseas shipping delays, strengthening its service to domestic customers. The move is part of Eastman Kodak's broader strategy to enhance its position in pharmaceutical manufacturing and reinforce local supply chains.

Kodak has recently moved to deploy its expertise in chemicals and coatings to drive growth in battery and pharmaceutical sectors, according to a previous announcement about its business expansion. The company has also extended its global supply chain operations, focusing on reliability in delivering film, printing plates and advanced materials to international customers. These steps align with Kodak’s ongoing push into advanced manufacturing.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.